Influence of chlorthalidone on the pharmacokinetics and pharmacodynamics of Org 10172 (Lomoparan), a low molecular weight heparinoid, in healthy volunteers
- PMID: 1716644
- DOI: 10.1002/j.1552-4604.1991.tb03746.x
Influence of chlorthalidone on the pharmacokinetics and pharmacodynamics of Org 10172 (Lomoparan), a low molecular weight heparinoid, in healthy volunteers
Abstract
The influence of chlorthalidone (100 mg PO) on the pharmacokinetics and pharmacodynamics of Org 10172 (IV bolus injection of 3250 anti-Xa units), a low molecular weight heparinoid, was studied in six healthy male volunteers using an open randomized two-way crossover design. Chlorthalidone produced a slight decrease in clearance of anti-Xa activity from 7.1 +/- 1.0 to 6.6 +/- 0.8 mL/min and a decrease of the volume of distribution from 0.20 +/- 0.05 to 0.16 +/- 0.04 L/kg, whereas the volume of distribution of antithrombin activity increased from 0.14 +/- 0.05 to 0.26 +/- 0.10 L/kg (all differences P less than .05). During the entire study period no adverse events occurred. In summary, chlorthalidone showed separate effects on different fractions of Org 10172. The clinical implication of the slight change observed in plasma anti-Xa activity is likely to be limited, whereas the 80% increase in distribution volume of plasma antithrombin activity can not be defined as yet in terms of clinical relevance.
Similar articles
-
Interaction of the combined medication with the new low-molecular-weight heparinoid Lomoparan (Org 10172) and acenocoumarol.Haemostasis. 1990;20(3):136-46. doi: 10.1159/000216120. Haemostasis. 1990. PMID: 1696921 Clinical Trial.
-
Interaction of ORG 10172, a low molecular weight heparinoid, and digoxin in healthy volunteers.Eur J Clin Pharmacol. 1991;41(3):245-50. doi: 10.1007/BF00315437. Eur J Clin Pharmacol. 1991. PMID: 1748141 Clinical Trial.
-
The influence of Org 10172, a low molecular weight heparinoid, on antipyrine metabolism and the effect of enzyme induction on the response to Org 10172.Br J Clin Pharmacol. 1991 Jul;32(1):23-9. doi: 10.1111/j.1365-2125.1991.tb05608.x. Br J Clin Pharmacol. 1991. PMID: 1716140 Free PMC article.
-
Pharmacokinetic considerations on Orgaran (Org 10172) therapy.Haemostasis. 1992;22(2):73-84. doi: 10.1159/000216298. Haemostasis. 1992. PMID: 1379967 Review.
-
Orgaran (Org 10172): its pharmacological profile in experimental models.Haemostasis. 1992;22(2):58-65. doi: 10.1159/000216296. Haemostasis. 1992. PMID: 1379965 Review.
Cited by
-
Danaparoid: a review of its use in thromboembolic and coagulation disorders.Drugs. 2002;62(15):2283-314. doi: 10.2165/00003495-200262150-00016. Drugs. 2002. PMID: 12381232 Review.
-
Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.Drugs. 1997 Dec;54(6):903-24. doi: 10.2165/00003495-199754060-00008. Drugs. 1997. PMID: 9421696 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources